The Oncology Institute
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of The Oncology Institute generated cash of -$36,315,000, which is more than the previous year. Cash used in financing activities reached the amount of -$6,847,000 last year. Net change in cash is therefore $19,478,000.
Cash Flow
| 2018 | 5.64M | 2.48M | -8.20M |
|---|---|---|---|
| 2019 | 3.61M | -1.20M | -1.81K |
| 2020 | 508.23K | -8.84M | 11.88M |
| 2021 | -32.68M | -12.15M | 154.01M |
| 2022 | -61.75M | -131.61M | 92.20M |
| 2023 | -36.31M | 62.64M | -6.84M |
TOIIW Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 14.01M | 115.17M | 5.99M | 2.44M | 37.31K | 52.00K |
Operating activities | ||||||
Net income | -83.06M | 1.65M | -10.92M | -14.32M | -4.02M | 3.94M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 5.87M | 4.41M | 3.34M | 3.17M | 2.94M | 1.10M |
Stock-based compensation expense | 17.81M | 27.68M | 24.53M | 151K | 94.00K | 0 |
| Deferred income tax benefit | 17.81M | 27.68M | 24.53M | 151K | 94.00K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -4.49M | -20.28M | -2.19M | -6.76M | -4.32M | -1.38M |
Inventories | -4.38M | -1.73M | -1.84M | -465.24K | -1.13M | -296.76K |
Accounts payable | 5.05M | -6.18M | 2.91M | 3.75M | 5.52M | 6.07M |
Cash generated by operating activities | -36.31M | -61.75M | -32.68M | 508.23K | 3.61M | 5.64M |
Investing activities | ||||||
Purchases Of Investments | -9.59M | -117.50M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -4.56M | -5.52M | -3.04M | -1.19M | -1.20M | -695.96K |
Acquisitions Net | -4.45M | -8.57M | -9.10M | -150K | 0 | 3.18M |
Cash generated by investing activities | 62.64M | -131.61M | -12.15M | -8.84M | -1.20M | 2.48M |
Financing activities | ||||||
Common Stock Issued | 126K | 858K | 20M | -293K | 25K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | -8.20M |
Repurchases of common stock | -1.01M | -9M | 0 | 0 | 0 | 0 |
Repayments of term debt | -101K | 109.94M | -7.25M | -12.18M | -1.81K | 0 |
Cash used in financing activities | -6.84M | 92.20M | 154.01M | 11.88M | -1.81K | -8.20M |
Net Change In Cash | 19.47M | -101.16M | 109.17M | 3.55M | 2.40M | -14.68K |
Cash at end of period | 33.48M | 14.01M | 115.17M | 5.99M | 2.44M | 37.31K |
| Data source | Data source | Data source | Data source |